Effects of combination therapy on p21 expression <i>in vivo</i> and <i>in vitro</i>.

<p>(A) Immunohistochemistry (IHC) staining for p21 in tumor xenograft tissues. Mice were treated with placebo or combination therapy (Gefitinib 2 mg/day, 5 times per week and DIM-C 60 mg/Kg, 3 times per week). Graphic on the right side represents quantification of positive staining cells. (B) In vitro expression of p21 in Western blot of lysate cells treated with gefitinib 5 µM and DIM-C 3 µM for 24 hs. Graphic on the right side, represents quantification of p21 expression related to GAPDH.